GOLDMAN SACHS GROUP INC (WSLS OFFSHORE INVESTMENTS, SLP) sold $2.3M of ATTO (indirect holdings)
GOLDMAN SACHS GROUP INC sold 105,807 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $21.28 ($20.84–$22.19, $2.25M total) across 23 trades on 2026-08-05. Filed jointly with GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P. and WSLS EMP ONSHORE INVESTMENTS, L.P..
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the open-market sale totaling about $2.25M and the resulting 0-share position for the reporting group’s indirect holdings.
Market read
Traders may monitor ATTO for any clustering of similar sales by other holders, but this filing alone does not provide a new fundamental catalyst.
What to watch
Indirect holdings and multi-entity joint filers can obscure who ultimately bears the economic exposure; absence of a stated 10b5-1 plan does not confirm information content.
Background
This is an SEC Form 4 insider transaction disclosure for Attovia Therapeutics, Inc. (ATTO), reported by Goldman Sachs Group Inc and related entities as indirect holders.
Ticker impact
Goldman Sachs Group reported an indirect open-market sale of 105,807 ATTO shares at a weighted avg $21.2808, leaving 0 shares.
Likely limited, short-lived sentiment impact; any follow-through would depend on whether other holders also reduce exposure.
Form 4 shows a one-time sale with no 10b5-1 plan stated and no accompanying company-specific news (no guidance, trial, or deal). The transaction size is moderate, and indirect sales often have non-informational motives.
Market effects
Minimal sector read-through because the disclosure is a single-company insider sale without operational or regulatory context.
None indicated.
None indicated.
Counterpoint
The sale could be routine rebalancing or tax-related, so it may not reflect negative expectations for ATTO.
Key entities
- issuerAttovia Therapeutics, Inc.
Subject of the Form 4 disclosure; 105,807 shares sold indirectly, leaving 0 shares.
- reporting_ownerGoldman Sachs Group Inc
Reporter of the indirect open-market sale via multiple co-reporting entities.